Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

bioMerieux and Shanghai Kehua Bio-engineering forges Chinese joint venture

BioMerieux : 01 February, 2008  (New Product)
Shanghai Kehua Bio-engineering and bioMerieux have created a Shanghai-based joint venture that will see bioMerieux transfer microplate immunoassay manufacturing currently located at its Boxtel site in the Netherlands.

bioMerieux will hold 60 percent of the capital in the joint venture. The alliance brings together Kehua’s strong manufacturing and development capabilities with bioMerieux’s expertise in immunoassays and infectious disease diagnostics.

The microplate range manufactured by the joint venture will be distributed by bioMerieux in the Europe, Middle East and Africa, Asia-Pacific (including China) and Latin America regions.

The two companies are also exploring opportunities for bioMerieux to distribute Kehua’s diagnostics through its extensive global network as part of a broader, long-term partnership.

“bioMerieux is a world famous company in the field of diagnostics, with extensive experience and strong global reputation. The cooperation will benefit both parties from brand image, sales network and complementary products pipeline,” stated Tang Wei Guo, board chairman of Kehua.

“Kehua is the market leader in Chinese diagnostics, with a proven track record of providing high quality, cost-efficient products,” stated Stephane Bancel, chief executive officer of bioMerieux. “Microplate immunoassays play an important role in public health. The alliance with Kehua will enable bioMerieux to provide this product line to our customers at a competitive price, thanks to an improved cost structure,” he added.

The transfer of manufacturing will be made progressively during 2008 and 2009 until the Dutch site’s closure.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo